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This report describes the presence and activity of 1,25-dihydroxyvitamin D3 (1,25-D3) in experimental bovine
tuberculosis. Animals that went on to develop tuberculous lesions exhibited a rapid transient increase in serum
1,25-D3 within the first 2 weeks following infection with Mycobacterium bovis. 1,25-D3-positive mononuclear
cells were later identified in all tuberculous granulomas by immunohistochemical staining of postmortem
lymph node tissue. These results suggest a role for 1,25-D3 both at the onset of infection and in the development
of the granuloma in these infected animals. Using a monoclonal antibody to the vitamin D receptor (VDR) as
a VDR agonist, we confirmed that activation of the vitamin D pathway profoundly depresses antigen-specific,
but not mitogenic, bovine peripheral blood T-cell responses (proliferation and gamma interferon production).
Investigation of the mechanism of this suppression showed that the VDR antibody modified the expression of
CD80 by accessory cells, such that a significant positive correlation between T-cell proliferation and accessory
cell CD80 emerged.
Sunshine and cod liver oil both have a long association with
the treatment of tuberculosis and represent the two sources of
vitamin D available, via UV irradiation of the skin and diet.
Reports from the mid-19th century suggest that vitamin D in
the form of cod liver oil was beneficial in the treatment of
tuberculosis, and calcium therapy with or without vitamin D
was used before specific chemotherapy became available (18).
More recent reports have associated low or disturbed serum
vitamin D levels with increased susceptibility to tuberculosis
(13, 18, 20, 51), and this is supported by genetic linkage studies
of vitamin D receptor (VDR) gene polymorphism that indicate
an association between the VDR and susceptibility or resis-
tance to tuberculosis (5, 44, 45, 51).
The active component of vitamin D, 1,25-dihydroxyvitamin
D3 (1,25-D3) acts exclusively via its specific nuclear receptor
(49), and therefore the distribution of the VDR within the
immune system provides information on the active sites of this
steroid hormone. The VDR is constitutively expressed in hu-
man peripheral monocytes but can be induced in activated
lymphocytes (6, 36). VDR expression in both monocytes and T
cells can be further up-regulated by exposure to 1,25-D3.
1,25-D3 production by monocytes and macrophages has long
been recognized (1, 26, 31), but it is also now apparent that T
cells could equally be a major site of 1,25-D3 activity (7, 11, 47),
and this may also be the case in tuberculosis (7, 11).
It is becoming increasingly accepted that 1,25-D3 has an
important role in the development of immune responses. Re-
ported activities of 1,25-D3 include the suppression of T-cell
proliferation (40), inhibition of gamma interferon (IFN-) and
interleukin-2 (IL-2) production (15, 25), differential regulation
of CXC and CC chemokines (29), and enhanced generation of
regulatory (23) and Th2 (8) T cells. Some of the effects of
1,25-D3 on T-cell responses are thought to be indirect via the
antigen-presenting cell. Reports describe a reduced ability of
monocytes to induce antigen-dependent T-cell proliferation,
which is now known to be at least partly due to alterations in
antigen-presenting and costimulatory molecules, and the retar-
dation of dendritic cell development (12, 33, 34, 39).
In this report we describe the presence and activity of
1,25-D3 in cattle infected with Mycobacterium bovis. Bovine
tuberculosis is an increasing problem in the United Kingdom
herd, despite a government test-and-slaughter policy (35), and
has led to an independent scientific review (28) that advocates
the production of new and improved vaccines and diagnostic
reagents. Underpinning this work is the investigation of the
immunology of bovine tuberculosis, using an experimental reg-
imen that generates pathology similar to that seen in naturally
infected cattle (10). Using this experimental approach, we in-
vestigated the kinetics of serum 1,25-D3 following infection
and the presence of 1,25-D3 within the tuberculous granuloma.
The effects of VDR activation on antigen-specific lymphocyte
responses were also assessed.
MATERIALS AND METHODS
Animals. This study utilized eight Friesian cows from tuberculosis-free herds
that were infected intratracheally with either 4  105 CFU (four animals), 6 
104 CFU (two animals) or 6  103 CFU (two animals) of virulent M. bovis
(AF2122/97). A naturally exposed M. bovis field reactor was also included in
certain experiments as indicated. Sequential serum samples were taken from all
experimentally infected animals. The experiments described were carried out
with experimentally infected animals approximately 3 to 4 weeks prior to slaugh-
ter (ca. 17 weeks postinfection). The tuberculin skin test was carried out 2 weeks
prior to slaughter of these experimentally infected cattle. Cattle exposed to the
two higher doses of M. bovis (4  105 and 6  104 CFU) converted to skin test
positivity. Cattle exposed to the lower dose of M. bovis (6  103 CFU) remained
skin test negative. Euthanasia was carried out at approximately 20 weeks postin-
fection by intravenous injection of sodium pentobarbitone, and a detailed post-
mortem analysis was performed. Skin test-positive animals all presented with
gross tuberculous lesions typical of natural bovine tuberculosis. Lymph nodes
affected included the lateral and medial retropharyngeal, submandibular, bron-
chial, and mediastinal lymph nodes. Lung lesions were also identified. Lesions
were confirmed as tuberculous by histopathological staining and M. bovis culture
from affected tissues. No lesions were identified in either of the skin test-negative
animals. Acid-fast bacilli could not be found in any tissues from these two
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low-dose-infected animals, which were also M. bovis culture negative. In addition
to M. bovis-infected animals, we utilized a group of eight M. bovis BCG-vacci-
nated cattle in our final experiment. These animals were Fresian cows from
tuberculosis-free herds that had been vaccinated subcutaneously with two doses
(8 weeks apart) of 106 CFU of M. bovis BCG-Pasteur. The experiment described
was carried out with these animals 2 weeks after their second dose of BCG-
Pasteur, when strong specific immune responses (IFN- and proliferation) were
still apparent.
Immunohistochemistry. Lymph nodes (left bronchial and left medial retro-
pharyngeal in this investigation) were removed at postmortem, cut into approx-
imately 0.3- by 0.5- by 1.0-cm pieces, fixed in 10% buffered formalin, and
processed and embedded in paraffin wax by standard histological procedures.
Four-micrometer sections were cut and stored at 4°C until required. Sections
were brought to room temperature and dewaxed in xylene (three times for 6 min)
followed by absolute ethanol (two times for 6 min). Endogenous peroxidase was
blocked by incubation in 1% H2O2 in methanol for 15 min. The sections were
then rinsed in running water for 5 min before incubation in 1% Triton X-100
(Merck, Poole, Dorset, United Kingdom) in water for 90 s. Sections were rinsed
again in running water for 5 min and finally washed twice in Tris-buffered saline
(TBS). Epitope demasking was carried out by incubating sections in a 50:50 mix
of trypsin-chymotrypsin (Sigma, Poole, Dorset, United Kingdom) at a total
concentration of 1 mg/ml in 0.1% CaCl2 (pH 7.8) for 10 min at 37°C. The
sections were then rinsed in running water for 10 min and washed twice in TBS.
Sections were blocked in 2% normal goat serum (NGS) in TBS for 2 h at room
temperature. Excess buffer was then blotted off, primary antibody (mouse anti-
1,25-D3 [Biogenesis, Poole, Dorset] or normal mouse serum control [Sigma]
diluted 1/100 in TBS–2% NGS) was added, and sections were incubated over-
night at 4°C. The sections were washed three times in TBS, and biotinylated goat
anti-mouse immunoglobulins (Vector Laboratories, Peterborough, United King-
dom) diluted 1/200 in TBS–2% NGS was added and left for 30 min at room
temperature. Sections were washed three times in TBS, and 1,25-vitamin D
staining was enhanced and visualized by using Vectastain Elite ABC reagent
(Vector Laboratories) followed by diaminobenzidine substrate (Vector Labora-
tories). The sections were rinsed for 5 min in running water and then dehydrated
through increasing concentrations of ethanol and cleared in xylene before
mounting with Vectamount (Vector Laboratories).
Serum 1,25-vitamin D3. 1,25-D3 in serum samples was measured by using a
radiometric assay kit specific for the active vitamin D molecule (IDS Ltd., Tyne
and Wear, United Kingdom) according to the manufacturer’s instructions. Re-
sults were determined with a Wallac gamma counter and expressed as picomolar
concentrations.
Lymphocyte proliferation assay. Peripheral blood mononuclear cells (PBMC)
were separated from whole blood by centrifugation on Histopaque-1077 (Sigma).
PBMC were washed in Hanks balanced salt solution (HBSS) (Life Technologies,
Paisley, Scotland) twice, and viable cells were counted by trypan blue dye exclu-
sion and set to 2  106/ml in culture medium (RPMI with Glutamax and 25 mM
HEPES [Life Technologies] supplemented with 5% controlled protein supple-
ment replacement 1 [Sigma], 100 U of penicillin per ml, 100 g of streptomycin
[Life Technologies] per ml, MEM nonessential amino acids [Sigma], and 5 
105 M 2-mercaptoethanol [Life Technologies]). A total of 2 105 cells per well
were incubated in 96-well flat-bottomed plates (Nunc, Life Technologies) in
triplicate with antigen (bovine tuberculin purified protein derivative [PPD-B], 10
g/ml; ESAT-6, 5 g/ml), concanavalin A (ConA) (5 g/ml), and medium only
as a control. Rat anti-VDR antibody (rat immunoglobulin G2b [IgG2b] ascites;
Biogenesis) was titrated into the cultures at final dilutions of 1/100, 1/200, 1/400,
and 1/800. The concentration of specific antibody in the ascites was not known,
and therefore we used two control rat antibodies diluted as described above: an
isotype control rat IgG2b (Biogenesis), also of unknown concentration, and a
total rat IgG (Sigma) with a stock concentration of 10 mg/ml (hence the final
concentrations following dilution of this IgG control antibody were known to be
100 g/ml [1/100], 50 g/ml [1/200], 25 g/ml [1/400], and 12.5 g/ml [1/800]).
Cultures were incubated for 5 days at 37°C with 5% CO2, pulsed with tritiated
thymidine (Amersham, Little Chalfont, United Kingdom) at 1Ci/well, incu-
bated for a further 24 h, and harvested, and results were determined by beta-
scintillation counting.
IFN- enzyme-linked immunosorbent assay. IFN- was measured in the cul-
ture supernatants of PBMC after 6 days of stimulation with PPD-B and in
no-antigen controls by using the Bovigam enzyme-linked immunosorbent assay
kit (Biocor, AH, Omaha, Nebr.) according to the manufacturer’s instructions.
Flow cytometry. PBMC were incubated at 2  106/ml in 5-ml volumes in
six-well plates (Costar; Corning Inc., High Wycombe, United Kingdom) in the
presence of PPD-B (10 g/ml) or PPD-B plus anti-VDR antibody at a 1/400 final
dilution. On day 6 of the culture, adherent cells were harvested from each well;
nonadherent cells were removed by gently resuspending with a pipette, followed
by two washes with 5 ml of warm (37°C) culture medium. The medium was
removed, and adherent cells were lifted by incubation for 10 to 20 min in 5 ml of
nonenzymatic cell dissociation medium (Sigma). Cells were then washed once in
HBSS (Gibco, Life Technologies) and divided into the wells of a 96-well V-
bottom plate (Nunc, Life Technologies) for staining with monoclonal antibodies.
The cells were washed once, and cell pellets were suspended in 30 l of primary
antibodies for CD80 (IL-A159) and CD86 (IL-A190) (both provided by N.
MacHugh, Centre for Tropical Medicine, Roslin, United Kingdom.), CD40,
major histocompatibility complex (MHC) class I (IL-A88), and MHC class II
(CC-158). The isotype control antibodies used were TRT-1 (IgG1) and TRT-3
(IgG2a). All antibodies (except IL-A159 and IL-A190) were produced at the
Institute for Animal Health. Antibodies were diluted in HBSS containing 1%
bovine serum albumin (BSA) (Sigma) and 0.1% sodium azide (Sigma) where
appropriate. Cells were incubated with the primary antibodies for 30 min on ice,
washed once in HBSS-BSA-azide, and then resuspended in 30 l of fluorescein
isothiocyanate-conjugated sheep anti-mouse immunoglobulins (Vector Labora-
tories) diluted 1/50 in HBSS-BSA-azide for 30 min on ice. The cells were then
washed once, resuspended in 4% paraformaldehyde–phosphate-buffered saline,
and stored at 4°C until analysis with a FACScan and CellQuest software (Becton
Dickinson, Oxford, United Kingdom). The percent positive staining for each
surface marker in each animal for each culture condition (i.e., PPD-B only or
PPD-B plus anti-VDR) was then generated by subtracting the percent back-
ground isotype control staining from the specific staining for each surface
marker.
Statistics. Paired t tests were used for the data in Fig. 4 to compare the
inhibition of proliferation using VDR antibody with the antibody controls
(IgG2b and IgG). Linear regression to measure correlation coefficients was
carried out for the data in Fig. 5 and 6. The data were found to follow a Gaussian
distribution and were therefore analyzed by using Pearson’s product moment
correlation. All statistical analyses were carried out with Prism software (Graph-
Pad Software Inc., San Diego, Calif.) using 95% confidence intervals.
RESULTS
Rapid mobilization of serum 1,25-D3 following infection.
Figure 1 shows the serum 1,25-D3 concentrations in four ani-
mals prior to (week 0) and following exposure to virulent M.
bovis. Each graph shows the results for one animal, monitored
over a 20-week period. Figure 1a and b show the results for the
two animals exposed to 6  104 CFU of M. bovis, which are
representative of those for all six skin test-positive experimen-
tally infected animals in this study. Figure 1c and d show the
results for the two animals exposed to the lowest dose of 6 
103 CFU of M. bovis, which remained skin test negative. The
prechallenge serum 1,25-D3 levels ranged from 52 to 138 pM
between individuals. Following infection, serum 1,25-D3 in-
creased in all skin test-positive animals (peak levels of 132 to
200 pM within the group). This rapid increase in 1,25-D3 was
transient, lasting 1 to 2 weeks, after which time the levels of
1,25-D3 dropped and gradually returned to preexposure levels.
In contrast, the two animals exposed to the lowest dose (6 
103 CFU) of M. bovis and that had remained skin test negative
(Fig. 1c and d) did not exhibit such an increase in serum
1,25-D3, but instead the levels remained relatively stable (Fig.
1c) or even appeared to decrease (Fig. 1d) following exposure
to M. bovis. Collectively, these results suggest a rapid mobili-
zation of 1,25-D3 following exposure of cattle to M. bovis that
can be detected in serum early (0 to 2 weeks) after infection,
indicating a role for 1,25-D3 at the onset of host reactivity.
However, the role of 1,25-D3 may be affected by the pathogen
dose.
Lymphocytes within the granuloma produce 1,25-D3. Figure
2 shows the immunohistochemical staining of an infected left
bronchial lymph node section from one representative animal
at magnifications of 20 (Fig. 2a) and 100 (Fig. 2b). Figure
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2a shows that 1,25-D3-positive cells (stained brown) were con-
centrated almost exclusively within the granuloma, with very
few 1,25-D3-positive cells present in the surrounding lymphoid
tissue. Figure 2b shows these 1,25-D3-positive cells to be
mononuclear cells. This concentration of 1,25-D3-positive cells
within the granuloma was found in all animals investigated (six
experimentally infected animals) and in all granulomas, large
or small, suggesting that 1,25-D3 has an important role in
FIG. 1. Serum 1,25-D3 concentrations in four individual cattle prior to and following exposure to M. bovis. (a and b) Cattle exposed to 6  10
4
CFU; (c and d) cattle exposed to 6  103 CFU. Concentrations in serum were measured with a commercial radiometric assay.
FIG. 2. Sections of lymph node tissue (left bronchial) from one representative animal stained with a monoclonal antibody to 1,25-D3. Sections
show a granuloma at magnifications of 20 (a) and 100 (b). 1,25-D3-positive mononuclear cells are stained brown.
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granuloma development and/or maintenance in bovine tuber-
culosis.
VDR ligation down-regulates T-cell responses. We next in-
vestigated the effects of 1,25-D3 on peripheral T-cell responses
in both experimentally infected and naturally exposed animals.
To exert its effect, 1,25-D3 must bind and activate the nuclear
VDR. This allows the mobilization of the VDR into the nu-
cleus, where it binds to specific response elements within the
promoter regions of target genes (9). We found that a com-
mercially available monoclonal antibody raised against the
VDR acted as an agonist, in that this specific VDR antibody
inhibited lymphocyte proliferation in a dose-dependent man-
ner. Figure 3 shows the increased inhibition of PBMC prolif-
eration of a naturally exposed field reactor animal with in-
creased concentration (lower dilution) of VDR antibody. Two
different rat antibody controls were incorporated in these ex-
periments, an isotype-matched IgG2b and a total IgG (see
Materials and Methods) used at the same dilutions as the
anti-VDR antibody. Figure 3a and b show the effect of VDR
antibody on proliferation to the dominant mycobacterial anti-
gen ESAT-6 and the mitogen ConA, respectively. These re-
sults show that the inhibition by the VDR antibody is depen-
dent upon antibody concentration within the culture, as the
effect titrates out with increased dilution. It can be seen that at
a dilution of 1/400, the inhibition of antigen-specific prolifer-
ation remains high (85%) while the inhibition of mitogenic
proliferation is low (20%). The inhibitory effects of control
antibodies were minimal in comparison at this antibody dilu-
tion. We therefore chose 1/400 for subsequent experiments
using this antibody.
The inhibitory effect of the VDR antibody was then tested in
a group of seven infected animals. Figure 4 shows the mean
inhibition of proliferation induced by the VDR antibody in six
experimentally infected animals plus the M. bovis field reactor
(see above) to PPD-B, ESAT-6, and ConA. Antigen-specific
responses were effectively blocked by the VDR antibody
(95% inhibition by antibody at a 1/400 final dilution), while
mitogenic responses were barely affected (the mean represents
one animal at 39% inhibition plus six animals with zero inhi-
bition of ConA proliferation). Inhibition of antigen (PPD-B or
ESAT-6)-specific proliferation by the VDR antibody was sta-
tistically significant compared with that by either the IgG2b or
IgG control antibody (P  0.0001 in all cases).
In a repeat experiment using five experimentally infected
FIG. 3. Inhibition of PBMC proliferation to ESAT-6 (a) and ConA (b) by a monoclonal antibody to the VDR. Antigen and mitogen
concentrations were both 5 g/ml. Antibodies were at final dilutions of 1/100, 1/200, 1/400, and 1/800. The anti-VDR antibody (IgG2b) was of
unknown concentration, and therefore two control antibodies were used: an IgG2b isotype control (also of unknown concentration) and a total
IgG control of known concentration (12.5 g/ml at 1/800, 25 g/ml at 1/400, 50 g/ml at 1/200, and 100 g/ml at 1/100). Results are expressed as
the percent inhibition of proliferation compared to cultures of PBMC plus antigen or mitogen (no antibody). The vertical dashed lines indicate
the chosen dilution of antibody (1/400) for subsequent experiments.
FIG. 4. Inhibition of PBMC proliferation of seven animals (six
experimentally infected animals and one naturally exposed field reac-
tor) to antigen (PPD-B and ESAT-6) and mitogen (ConA) by the
VDR antibody. Anti-VDR and control antibodies were used at a final
dilution of 1/400 in PBMC cultures. The results are expressed as the
mean (plus standard deviation) inhibition of proliferation compared to
cultures of PBMC plus antigen or mitogen (no antibody). The VDR
antibody (solid bars) significantly inhibited the proliferative response
of PBMC to both PPD-B and ESAT-6 compared with either control
antibody (IgG2b [shaded bars] or IgG [open bars]) (P  0.0001 in all
cases).
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animals, we also confirmed the inhibitory effect of the VDR
antibody on PPD-B-induced IFN- production. VDR antibody
was again used at 1/400. Figure 5 shows the correlation be-
tween the inhibition of proliferation and the inhibition of
IFN- production by PBMC in these animals. In this experi-
ment the inhibition caused by the VDR antibody was more
variable than that in the previous experiment with the same
animals, with ranges of inhibition of 0 to 84% for proliferation
and 24 to 96% for IFN-. However, a significant positive cor-
relation (r2  0.9254; P  0.0088) was observed between the
inhibition of proliferation and inhibition of IFN- production
mediated by the VDR antibody, demonstrating the potential of
vitamin D to interfere with antigen-specific type 1 responses in
these animals.
VDR ligation modifies CD80 expression on antigen-present-
ing cells. In the light of the results obtained above, i.e., inhi-
bition of antigen-specific rather than mitogenic responses, we
reasoned that the effects of the VDR antibody were indirect,
via the antigen-presenting cell. We therefore investigated the
effect(s) of the VDR antibody upon MHC and costimulatory
molecule expression by accessory cells within antigen-stimu-
lated PBMC. This last experiment was carried out with PBMC
from a group of eight BCG-vaccinated cattle, as M. bovis-
infected cattle were not available at this time. These animals
were all responding well to PPD-B, and PPD-B-specific PBMC
proliferation could be inhibited by the VDR antibody as shown
for M. bovis-infected animals above. PBMC were cultured in
bulk in six-well plates, with PPD-B in the presence or absence
of a 1/400 dilution of VDR antibody. After 6 days, the adher-
ent cells were harvested, washed, and labeled with monoclonal
antibodies specific for the surface molecules MHC class I,
MHC class II, CD80, CD86, and CD40. Percent positive stain-
ing was calculated by using isotype-matched control antibodies.
Figure 6 shows the correlation between PBMC proliferation
to PPD-B and the percentage of CD80-positive cells within the
adherent cell population of PPD-B-stimulated PBMC follow-
ing culture with VDR antibody. Proliferation inhibition by
VDR antibody varied in this group of animals from zero to
66%. The percentage of CD80-positive cells within the adher-
ent cell population, after subtracting the background staining
of the isotype-matched control antibody (background staining
was variable between individual animals), was low, and ranged
from zero to 8%. Nevertheless, these data clearly show a sig-
nificant correlation (r2  0.72; P  0.0079) between the per-
centage of CD80-positive adherent cells and the level of pro-
liferation within PBMC cultures, with the greatest
proliferation (lowest inhibition) in those cultures with the high-
est percentage of CD80-positive cells and the lowest prolifer-
ation (greatest inhibition) in those cultures with the lowest
percentage of CD80-positive cells. This correlation was not
apparent in PPD-B-stimulated cultures that did not contain the
VDR antibody. No other correlation was found between
PBMC proliferation and any of the other surface markers
investigated (MHC class I, MHC class II, CD86, or CD40).
This experiment suggests that CD80 expression by accessory
cells is important for antigen-specific T-cell responses and that
the expression of CD80 by accessory cells can be modified by
the activation of the vitamin D pathway.
DISCUSSION
In this study we have shown that the bioactive component of
vitamin D, 1,25-D3, is rapidly mobilized following infection of
cattle with M. bovis. This mobilization was identified as a tran-
sient increase in serum 1,25-D3 within 2 weeks of infection in
those animals that went on to develop tuberculous lesions. A
similar transient increase in plasma 1,25-D3 (mean increase
from 37 to 118 pM) has been reported for postparturient dairy
cattle (2) coincident with an increased susceptibility to other
infections, such as mastitis, metritis, and paratuberculosis (24).
Interestingly, dietary supplements of vitamin D and vitamin A
(which is known to enhance the effects of vitamin D) are
recommended for postparturient dairy cattle to prevent hy-
pocalcaemia (50). Whether such supplements, combined with
the increased 1,25-D3 levels in these animals at this time,
contribute to a lowered resistance to infection is an interesting
FIG. 5. Correlation between inhibition of proliferation and inhibi-
tion of IFN- production in PPD-B-stimulated PBMC cultures in
which anti-VDR (1/400 final dilution) was included. Each dot repre-
sents one experimentally infected animal. The data show a highly
significant positive correlation (r2  0.9254; P  0.0088) between the
inhibition of proliferation and IFN- production caused by anti-VDR
in these animals.
FIG. 6. Correlation between percentage of CD80 cells in the ad-
herent population of PBMC and proliferation of the PBMC cultures
after 6 days of incubation with PPD-B and VDR antibody (at a 1/400
final dilution). Each dot represents one BCG-vaccinated animal. The
data show a significant negative correlation (r2  0.72; P  0.0079)
between the proportion of CD80 accessory cells present and the level
of proliferation.
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question. Further to this, we found that two animals that were
exposed to a lower dose of M. bovis and that remained disease
free did not display any increase in serum 1,25-D3 following
exposure to M. bovis. We know that these animals were in-
fected, however, as specific IL-4 responses, but no consistent
IFN- responses, were detected (38).
The observed changes in serum 1,25-D3 occurred at least 2
weeks before specific immune responses (IFN-, IL-2, and
proliferation) generally begin to be detected in this infection
model (37), indicating a role for 1,25-D3 at the initiation of
host immune reactivity to M. bovis. This role could conceivably
include effects on cellular recruitment via modulation of che-
mokine production (29) and/or effects on early T-cell polariza-
tion (46) or apoptosis (14).
In those animals that went on to develop tuberculous le-
sions, 1,25-D3-positive mononuclear cells were identified
within every granuloma, clearly placing 1,25-D3 at the heart of
pathogenesis. Although we did not identify the cell type, pre-
vious reports have described the production of 1,25-D3 by local
and peripheral CD8 T cells (11) and the expression of the
VDR on both CD4 and CD8 T cells in human tuberculosis
(7). In addition to the above-mentioned activities of 1,25-D3 in
cellular recruitment and polarization, which could be impor-
tant within the granuloma, 1,25-D3 is also known to control the
monokines transforming growth factor 	 (27) and tumor ne-
crosis factor alpha (16), both of which have been identified in
human tuberculous granulomas (4, 21). Furthermore, 1,25-D3
is known to activate monocytes and macrophages to kill intra-
cellular mycobacteria (17, 19, 41, 42), at least in part via the
induction of nitric oxide. This suggests that the function of
1,25-D3 within the tuberculous lesion lies in the construction
and maintenance of the granuloma and the dampening of
potentially harmful inflammatory T-cell responses, while at the
same time activating macrophages to kill intracellular bacilli.
We further investigated the ability of 1,25-D3 to affect spe-
cific T-cell responses. The suppression of antigen-specific and
mitogenic bovine T-cell responses by 1,25-D3 has previously
been described (3), and a more recent study indicated that this
inhibitory activity of 1,25-D3 was also to be found in cattle
infected with M. bovis (48). We attempted to clarify this effect
of 1,25-D3 in our M. bovis-infected cattle by using a monoclo-
nal antibody raised against the VDR as a receptor agonist. We
found that addition of VDR antibody to antigen-stimulated
PBMC cultures could profoundly depress antigen-specific pro-
liferation and IFN- production but had a far lesser effect
upon mitogenic proliferation. We therefore hypothesized that
the observed effects of the VDR antibody on T-cell responses
in these animals were indirect, acting via the antigen-present-
ing cell by affecting either antigen-presenting (MHC class I and
MHC class II) or costimulatory (CD80, CD86, and CD40)
molecules.
We investigated the presence of these molecules by flow
cytometry on peripheral blood monocytes (plastic-adherent
cells) isolated from PBMC following stimulation with antigen,
with or without the addition of the VDR antibody. We found
that the addition of the VDR antibody modified the expression
of CD80 on accessory cells, such that a significant correlation
emerged between the percentage of CD80-positive cells
present and the level of PBMC proliferation observed in the
individual cultures. These results were surprising given that
these accessory cells would have been a heterogeneous popu-
lation of cells and that the percentages of CD80-positive cells
measured within the adherent cell populations were low (al-
though they were similar to levels measured in 3-day plastic-
adherent PBMC in other, unrelated experiments [J. Hope,
unpublished observations]). Our results therefore clearly sug-
gest that the expression of CD80 by accessory cells is an im-
portant factor for bovine antigen-specific T-cell responses and
that the modification of the expression of this molecule on
accessory cells represents one mechanism by which vitamin D
may affect downstream T-cell responses in cattle.
This conclusion is supported by murine studies that have
described the inhibition of Th1 cells by CD80 suppression on
Langerhans cells (32), the prevention of graft-versus-host dis-
ease by the blockade of Th1 responses with monoclonal anti-
bodies to CD80 and CD86 (43), and the correlation between
CD80-positive accessory cells and elevated Th1 responses in
experimental autoimmune encephalomyelitis (22). In addition,
CD80 expression by human and mouse accessory cells has been
shown to be crucial for the induction of CD4 cytotoxic T cells
(30). Whether such cytotoxic T cells are active in bovine tu-
berculosis is yet to be discovered.
In summary, our work on bovine tuberculosis supports a role
for 1,25-D3 at the very onset of infection with M. bovis and in
the development of pathogenesis. Our data support an anti-
inflammatory role for 1,25-D3 in the reduction of Th1 re-
sponses, for which the expression of accessory cell CD80 may
be important.
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